Table 1.
Patient characteristics among TNBC according to PD-L1-TC and PD-L1-IC expression.
| PDL-L1-TC | PDL-L1-IC | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | Class | Overall | Negative (0%) |
Positive (≥1%) |
p | Negative (0%) | Positive (≥1%) |
p |
| n= | 89 | 58 | 31 | 59 | 30 | |||
| Baseline Characteristics | ||||||||
| Age | 50.20 [39.40, 57.90] | 49.03 (10.87) | 49.16 (11.23) | 0.960 | 48.94 (10.54) | 49.34 (11.85) | 0.871 | |
| Family history | No | 68 (76.4) | 44 (75.9) | 24 (77.4) | 1.000 | 46 (78.0) | 22 (73.3) | 0.824 |
| Yes | 21 (23.6) | 14 (24.1) | 7 (22.6) | 13 (22.0) | 8 (26.7) | |||
| Menopausal status | Premenopausal | 51 (57.3) | 33 (56.9) | 18 (58.1) | 1.000 | 34 (57.6) | 17 (56.7) | 1.000 |
| Postmenopausal | 38 (42.7) | 25 (43.1) | 13 (41.9) | 25 (42.4) | 13 (43.3) | |||
| BMI classes | 18.5–24.9 | 47 (52.8) | 34 (58.6) | 13 (41.9) | 0.266 | 34 (57.6) | 13 (43.3) | 0.221 |
| <18.5 | 2 (2.2) | 2 (3.4) | 0 (0.0) | 2 (3.4) | 0 (0.0) | |||
| 25–29.9 | 22 (24.7) | 12 (20.7) | 10 (32.3) | 11 (18.6) | 11 (36.7) | |||
| >=30 | 18 (20.2) | 10 (17.2) | 8 (25.8) | 12 (20.3) | 6 (20.0) | |||
| Smoking status | Never | 61 (71.8) | 42 (75.0) | 19 (65.5) | 0.452 | 42 (73.7) | 19 (67.9) | 0.366 |
| Current | 12 (14.1) | 8 (14.3) | 4 (13.8) | 9 (15.8) | 3 (10.7) | |||
| Former | 12 (14.1) | 6 (10.7) | 6 (20.7) | 6 (10.5) | 6 (21.4) | |||
| Comorbidity | No | 35 (45.5) | 25 (49.0) | 10 (38.5) | 0.524 | 27 (51.9) | 8 (32.0) | 0.162 |
| Yes | 42 (54.5) | 26 (51.0) | 16 (61.5) | 25 (48.1) | 17 (68.0) | |||
| Clinicar T stage | T0–T1 | 6 (6.7) | 2 (3.4) | 4 (12.9) | 0.077 | 4 (6.8) | 2 (6.7) | 0.257 |
| T2 | 62 (69.7) | 39 (67.2) | 23 (74.2) | 38 (64.4) | 24 (80.0) | |||
| T3–T4 | 21 (23.6) | 17 (29.3) | 4 (12.9) | 17 (28.8) | 4 (13.3) | |||
| Clinical N stage | N0 | 38 (42.7) | 25 (43.1) | 13 (41.9) | 1.000 | 26 (44.1) | 12 (40.0) | 0.889 |
| N1–N2–N3 | 51 (57.3) | 33 (56.9) | 18 (58.1) | 33 (55.9) | 18 (60.0) | |||
| SBR grade | Grade I-II | 12 (13.8) | 11 (19.3) | 1 (3.3) | 0.084 | 10 (17.2) | 2 (6.9) | 0.323 |
| Grade III | 75 (86.2) | 46 (80.7) | 29 (96.7) | 48 (82.8) | 27 (93.1) | |||
| Mitotic index | 32.62 (25.80) | 23.00 [11.00, 40.25] | 35.50 [14.75, 52.75] | 0.165 | 24.00 [11.00, 41.00] | 30.00 [14.00, 52.00] | 0.283 | |
| Mitotic index class | [0,20) | 34 (41.5) | 24 (44.4) | 10 (35.7) | 0.600 | 24 (43.6) | 10 (37.0) | 0.740 |
| >=20 | 48 (58.5) | 30 (55.6) | 18 (64.3) | 31 (56.4) | 17 (63.0) | |||
| Ductal carcinoma in situ | No | 83 (93.3) | 53 (91.4) | 30 (96.8) | 0.601 | 55 (93.2) | 28 (93.3) | 1.000 |
| Yes | 6 (6.7) | 5 (8.6) | 1 (3.2) | 4 (6.8) | 2 (6.7) | |||
| % stromal lymphocytes | 25.00 [10.00, 40.00] | 20.00 [10.00, 30.00] | 30.00 [16.25, 40.00] | 0.053 | 25.00 [10.00, 32.50] | 25.00 [5.00, 40.00] | 0.823 | |
| BC surgery | Lumpectomy | 59 (66.3) | 41 (70.7) | 18 (58.1) | 0.334 | 42 (71.2) | 17 (56.7) | 0.257 |
| Mastectomy | 30 (33.7) | 17 (29.3) | 13 (41.9) | 17 (28.8) | 13 (43.3) | |||
| NAC regimen | anthra-taxans | 85 (95.5) | 55 (94.8) | 30 (96.8) | 0.761 | 56 (94.9) | 29 (96.7) | 0.773 |
| anthra | 3 (3.4) | 2 (3.4) | 1 (3.2) | 2 (3.4) | 1 (3.3) | |||
| taxanes | 1 (1.1) | 1 (1.7) | 0 (0.0) | 1 (1.7) | 0 (0.0) | |||
| Post-NAC characteristics | ||||||||
| ypN stage | 0 | 53 (59.6) | 35 (60.3) | 18 (58.1) | 0.109 | 33 (55.9) | 20 (66.7) | 0.065 |
| [1-3] | 22 (24.7) | 17 (29.3) | 5 (16.1) | 19 (32.2) | 3 (10.0) | |||
| [4-9] | 13 (14.6) | 5 (8.6) | 8 (25.8) | 6 (10.2) | 7 (23.3) | |||
| 10 and more | 1 (1.1) | 1 (1.7) | 0 (0.0) | 1 (1.7) | 0 (0.0) | |||
| RCB index | 2.12 [1.54, 2.98] | 2.03 [1.45, 2.56] | 2.27 [1.67, 3.72] | 0.035 | 2.19 [1.52, 2.76] | 2.10 [1.63, 3.45] | 0.456 | |
| RCB classes | RCB-I | 15 (17.2) | 12 (21.1) | 3 (10.0) | 0.040 | 13 (22.0) | 2 (7.1) | 0.185 |
| 53 (60.9) | 37 (64.9) | 16 (53.3) | 35 (59.3) | 18 (64.3) | ||||
| RCB-III | 19 (21.8) | 8 (14.0) | 11 (36.7) | 11 (18.6) | 8 (28.6) | |||
| KI67 status | [0,20) | 51 (57.3) | 34 (58.6) | 17 (54.8) | 0.905 | 34 (57.6) | 17 (56.7) | 1.000 |
| >=20 | 38 (42.7) | 24 (41.4) | 14 (45.2) | 25 (42.4) | 13 (43.3) | |||
| Mitotic index | 31.28 (40.93) | 15.00 [0.00, 47.00] | 25.00 [3.00, 70.00] | 0.036 | 17.00 [0.00, 50.00] | 14.00 [2.50, 51.50] | 0.541 | |
| Mitotic index class | [0,20) | 43 (55.1) | 29 (55.8) | 14 (53.8) | 1.000 | 28 (53.8) | 15 (57.7) | 0.936 |
| >=20 | 35 (44.9) | 23 (44.2) | 12 (46.2) | 24 (46.2) | 11 (42.3) | |||
| % stromal lymphocytes | 15.00 [10.00, 30.00] | 15.00 [10.00, 30.00] | 20.00 [6.25, 30.00] | 0.860 | 15.00 [10.00, 30.00] | 22.50 [5.00, 30.00] | 0.850 | |
| Lymphovascular invasion | No | 54 (70.1) | 32 (65.3) | 22 (78.6) | 0.335 | 32 (65.3) | 22 (78.6) | 0.335 |
| Yes | 23 (29.9) | 17 (34.7) | 6 (21.4) | 17 (34.7) | 6 (21.4) | |||
Abbreviations: TC = tumor cells; IC = immune cells; BMI = body mass index; T = tumor; N = node; SBR = grade Scarff-Bloom and Richardson; NAC = neoadjuvant chemotherapy; anthra-taxans = anthracyclines and taxanes; anthra = anthracyclines; RCB = Residual Cancer Burden. The “n” denotes the number of patients. In case of categorical variables, percentages are expressed between brackets. In case of continuous variables, mean value is reported. In case of nonnormal continuous variables, median value is reported, with interquartile range between brackets. Missing data: Smoking status, n = 4; Comorbidity, n = 12; SBR grade, n = 2; Mitotic index, n = 3; Mitotic index class, n = 7; % stromal lymphocytes, n = 2; RCB index, n = 2; RCB classes, n = 2; Mitotic index post-NAC, n = 7; Mitotic index class post-NAC, n = 11; % stromal lymphocytes post-NAC, n = 2; Lymphovascular invasion post-NAC, n = 12. NB = Pre-NAC Ki67 not displayed in the table due to the high among of missing values (n = 81). Among the patients with pre-NAC Ki67 available, all values were 20% or higher.